drugset / Trial / NCT00684255
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if a reduced intensity (RI) (non-myeloablative) chemoimmunotherapy followed by Allogeneic Stem Cell Transplantation AlloSCT (matched family donors and matched unrelated cord blood donors) will be well tolerated.
Timeline
- Start
- 2007-08
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 20 mg/m2 | — |
| Subject | Busulfan | Small molecule | 3.2 mg/kg | — |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |